argenx SE | ARGX - Operating Expenses

Stock Price
693.20
Daily Change
-1.00 -0.14%
Monthly
-2.45%
Yearly
37.43%
Q2 Forecast
678.23

argenx SE reported $904M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AstraZeneca USD 8.18B 4.35B Mar/2026
Genmab DKK 798M 235M Dec/2025
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
GRIFOLS EUR 1.45B 255.28M Mar/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Lakefront Biotherapeutics EUR 70.18M 50.08M Mar/2026
Qiagen NV USD 418.54M 23.25M Dec/2025
UCB EUR 2.96B 196M Dec/2025